TITLE

Targeting semaphorins in MS as a treatment strategy to promote remyelination: A tale of mice, rats and men

AUTHOR(S)
Kremer, David; Hartung, Hans-Peter; Küry, Patrick
PUB. DATE
November 2015
SOURCE
Multiple Sclerosis Journal;Nov2015, Vol. 21 Issue 13, p1616
SOURCE TYPE
Academic Journal
DOC. TYPE
Editorial
ABSTRACT
The authors reflect on a translational study of targeting semaphorins in multiple sclerosis (MS) treatment to improve remyelination. Topics discussed include the role of Sema7A inhibitory molecules in neuroinflammation, the expression of receptors in MS lesions, and potential targets of central nervous system (CNS) inflammation of MS treatment.
ACCESSION #
110716767

 

Related Articles

  • MRI aspects of the “inflammatory phase” of multiple sclerosis. Filippi, M.; Rocca, M. A. // Neurological Sciences;Dec2003 Supplement 5, Vol. 24, ps275 

    In early relapsing-remitting (RR) multiple sclerosis (MS), conventional magnetic resonance imaging (MRI) has proved to be a valuable tool to assess disease activity over time. However, conventional MRI can only provide gross estimates of irreversible tissue damage within and outside such...

  • Treatment of central nervous system inflammation with inhibitors of basement membrane degradation. PARISH, CHRISTOPHER R; HINDMARSH, ELIZABETH J; BARTLETT, MARK R; STAYKOVA, MARIA A; COWDEN, WILLIAM B; WILLENBORG, DAVID O; Parish, Chris // Immunology & Cell Biology;Feb1998, Vol. 76 Issue 1, p104 

    Currently available anti-inflammatory drugs for the treatment of multiple sclerosis (MS) and other inflammatory diseases are generally inadequate, with disease progression not being arrested by the treatments and undesirable side effects posing problems. In response to these deficiencies our...

  • Focal and diffuse cortical degenerative changes in a marmoset model of multiple sclerosis. Pomeroy, I. M.; Jordan, E. K.; Frank, J. A.; Matthews, P. M.; Esiri, M. M. // Multiple Sclerosis (13524585);May2010, Vol. 16 Issue 5, p537 

    Background: Degenerative features, such as neuronal, glial, synaptic and axonal loss, have been identified in neocortical and other grey matter structures in patients with multiple sclerosis, but mechanisms for neurodegeneration are unclear. Cortical demyelinating lesions are a potential cause...

  • Neurodegeneration in multiple sclerosis is a process separate from inflammation: Yes. Louapre, Céline; Lubetzki, Catherine // Multiple Sclerosis Journal;Nov2015, Vol. 21 Issue 13, p1626 

    The article discusses debates about the causes of neurodegeneration in multiple sclerosis (MS), a type of central nervous system (CNS) inflammatory disease. Topics discussed include how inflammation and neurodegeneration interplay over the disease course, the potential factors that influence...

  • Class 3 semaphorins influence oligodendrocyte precursor recruitment and remyelination in adult central nervous system. Piaton, Gabrièle; Aigrot, Marie-Stéphane; Williams, Anna; Moyon, Sarah; Tepavcevic, Vanja; Moutkine, Imane; Gras, Julien; Matho, Katherine S.; Schmitt, Alain; Soellner, Heidi; Huber, Andrea B.; Ravassard, Philippe; Lubetzki, Catherine // Brain: A Journal of Neurology;Apr2011, Vol. 134 Issue 4, p1156 

    Oligodendrocyte precursor cells, which persist in the adult central nervous system, are the main source of central nervous system remyelinating cells. In multiple sclerosis, some demyelinated plaques exhibit an oligodendroglial depopulation, raising the hypothesis of impaired oligodendrocyte...

  • From inflammation to degeneration: the lessons of clinical trials. Comi, G. // Neurological Sciences;Dec2003 Supplement 5, Vol. 24, ps295 

    About two-third of patients with multiple sclerosis (MS) accumulate severe disabilities before the age of 50. Disability depends mostly on axonal loss even if persistent conduction block also may be a contributing factor. Axonal loss is predominant in the early phase of the disease and is...

  • Biological markers of the inflammatory phase of multiple sclerosis. Uccelli, A.; Pedemonte, E.; Narciso, E.; Mancardi, G. // Neurological Sciences;Dec2003 Supplement 5, Vol. 24, ps271 

    The search for biological markers in multiple sclerosis (MS) has been spoiled by the intrinsic nature of the disease that occurs in a secluded organ which cannot be accessed by routine sampling. Thus, markers obtained so far from the peripheral blood of MS individuals are often of little...

  • Inflammation and degeneration in multiple sclerosis. Brück, W.; Stadelmann, C. // Neurological Sciences;Dec2003 Supplement 5, Vol. 24, ps265 

    Multiple (MS) sclerosis is a chronic inflammatory demyelinating disease of the central nervous system with the pathological hallmarks of inflammation, demyelination, axon loss and gliosis. In the initial relapsing-remitting phase of the disease, the inflammatory-demyelinating component seems to...

  • The Development of Cannabinoid CBII Receptor Agonists for the Treatment of Central Neuropathies. Rivers, Jack Rocky-Jay; Ashton, John Clive // Central Nervous System Agents in Medicinal Chemistry;Mar2010, Vol. 10 Issue 1, p47 

    Two cannabinoids receptors have been characterised in mammals; cannabinoid receptor type 1 (CBI) which is ubiquitous in the central nervous system (CNS), and cannabinoid receptor type 2 (CBII) that is expressed mainly in immune cells. Cannabinoids have been used in the treatment of nausea and...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics